Blood Collection

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
21Mitochondrial disease1
65Primary immunodeficiency1
201Angelman syndrome1
IDDisease name (Link within this page)Number of trials
229Autoimmune pulmonary alveolar proteinosis1
271Ankylosing spondylitis1

21. Mitochondrial disease


Clinical trials : 108 / Drugs : 107 - (DrugBank : 35) / Drug target genes : 48 - Drug target pathways : 110 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 866 / Drugs : 858 - (DrugBank : 122) / Drug target genes : 108 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

201. Angelman syndrome


Clinical trials : 40 / Drugs : 48 - (DrugBank : 11) / Drug target genes : 22 - Drug target pathways : 22 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

229. Autoimmune pulmonary alveolar proteinosis


Clinical trials : 49 / Drugs : 36 - (DrugBank : 6) / Drug target genes : 3 - Drug target pathways : 15 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

271. Ankylosing spondylitis


Clinical trials : 631 / Drugs : 405 - (DrugBank : 73) / Drug target genes : 38 - Drug target pathways : 144 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries